<div id="readability-page-1"><p>ALX Oncology (NASDAQ:ALXO - Get Free Report) is anticipated to post its  Q4 2025 results before the market opens on Friday, February 27th. Analysts expect ALX Oncology to post earnings of ($0.38) per share for the quarter. Investors are encouraged to explore the company's upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 27, 2026 at 8:30 AM ET.</p><h2>ALX Oncology Stock Down 5.8%</h2><p>NASDAQ:ALXO traded down $0.15 during trading hours on Friday, hitting $2.45. 497,699 shares of the stock traded hands, compared to its average volume of 911,652. The firm has a 50 day moving average price of $1.61 and a 200 day moving average price of $1.44. The firm has a market cap of $132.84 million, a price-to-earnings ratio of -1.21 and a beta of 0.51. ALX Oncology has a fifty-two week low of $0.40 and a fifty-two week high of $2.66. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.13. </p><h2>Analyst Ratings Changes</h2><p>Several equities research analysts recently issued reports on ALXO shares. Piper Sandler increased their price objective on ALX Oncology from $3.00 to $4.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, February 5th. Wall Street Zen raised shares of ALX Oncology from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Monday, December 22nd. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of ALX Oncology in a research note on Wednesday, January 21st. Finally, Jefferies Financial Group initiated coverage on shares of ALX Oncology in a report on Thursday, November 13th. They set a &#34;buy&#34; rating and a $4.00 price target on the stock. Four research analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has issued  a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $2.50.</p><p><b>Read Our Latest Analysis on ALXO</b></p><h2>Insider Activity at ALX Oncology</h2><p>In related news, Director Corey S. Goodman acquired 3,184,713 shares of the business's stock in a transaction that occurred on Monday, February 2nd. The shares were acquired at an average cost of $1.57 per share, with a total value of $4,999,999.41. Following the purchase, the director owned 8,453,038 shares of the company's stock, valued at approximately $13,271,269.66. The trade was a 60.45% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Corporate insiders own  21.00% of the company's stock. </p><h2>Hedge Funds Weigh In On ALX Oncology</h2><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bridgeway Capital Management LLC acquired a new position in  ALX Oncology in the 3rd quarter valued at $66,000.  Invesco Ltd. bought a new stake in  ALX Oncology during the 1st quarter valued at approximately $46,000.  AQR Capital Management LLC grew its holdings in  ALX Oncology by 183.6% in the 1st quarter. AQR Capital Management LLC now owns 119,050 shares of the company's stock valued at $74,000 after buying an additional 77,065 shares during the last quarter.  State Street Corp boosted its holdings in  ALX Oncology by 11.0% in the 4th quarter. State Street Corp now owns 124,228 shares of the company's stock valued at $140,000 after purchasing an additional 12,300 shares during the period.  Finally, Jane Street Group LLC acquired a new position in shares of  ALX Oncology in the second quarter valued at $84,000. Institutional investors and hedge funds own  97.97% of the company's stock. </p><h2>About ALX Oncology</h2> (Get Free Report)<p>ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company's mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.  </p><p>The lead candidate in ALX Oncology's pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than ALX Oncology</li><li>The gold chart Wall Street is terrified of…</li><li>Buy this Gold Stock Before May 2026</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>This $15 Stock Could Go Down as the #1 Stock of 2026</li><li>Unlocked: Elon Musk’s Next Big IPO</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxYTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxYTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in ALX Oncology Right Now?</h2><p>Before you consider ALX Oncology, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ALX Oncology wasn't on the list.</p><p>While ALX Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IBBQ

SBIO

ALXO

<p>ALX Oncology (NASDAQ:ALXO) is set to announce its Q4 2025 earnings on February 27, with analysts predicting a loss of $0.38 per share. The stock recently fell 5.8% to $2.45, with a market cap of $132.84 million. Analyst ratings vary, with Piper Sandler raising its price target to $4.00 and a consensus rating of "Moderate Buy". Insider activity includes a significant purchase by Director Corey S. Goodman. Institutional investors hold 97.97% of the stock, which focuses on developing immuno-oncology therapies.</p>

ALX Oncology (ALXO) Expected to Announce Earnings on Friday